Statement of Principles concerning narcolepsy (Reasonable Hypothesis) (No. 11 of 2022)

Narcolepsy is defined in section 7(2) as a chronic neurological disorder of sleep regulation and wakefulness characterised by disabling, excessive and irresistible daytime sleepiness lasting at least three months, with varying degrees of cataplexy, hypnagogic hallucinations and sleep paralysis. It includes both type 1 (with cataplexy and orexin deficiency) and type 2 (without cataplexy, normal orexin). Crucially, it excludes early onset narcolepsy (presumably diagnosed in childhood or adolescence) and daytime sleepiness caused by another condition that disrupts sleep duration or quality, such as circadian rhythm disorders, insufficient sleep or medication side effects. This means a claimant must first exclude other causes of sleepiness before the diagnosis can qualify.

The diagnosis must be established by appropriate clinical testing, including sleep studies, the multiple sleep latency test and measurement of orexin in cerebrospinal fluid. The instrument defers to clinical practice for the test thresholds. The ICD-10-AM code G47.4 is referenced for statistical purposes, but the definition in subsection (2) is the operative one.

Relevant service is defined in the Dictionary. It covers operational service, peacekeeping service, hazardous service and British nuclear test defence service under the VEA, plus warlike and non-warlike service under the MRCA. The factor must be related to that service under section 10(1). For clinical worsening factors, section 10(2) clarifies that they apply only where the person’s narcolepsy was suffered or contracted before or during (but did not arise out of) their relevant service. This prevents a service-related worsening of a pre-existing condition from being compensated unless the worsening factor itself is service-related.

Reasonable hypothesis is not defined in the instrument but is the legal standard imported from the VEA. It requires that the factor be more than a mere possibility; there must be a plausible causal pathway supported by sound medical-scientific evidence. The RMA determines the factors based on that evidence (section 8), but the final decision on whether a reasonable hypothesis exists for a particular claim rests with the primary decision-maker or tribunal.

Clinical onset versus clinical worsening: The instrument provides 17 factors in section 9. Factors 1 to 8 relate to clinical onset (the first appearance of narcolepsy). Factors 9 to 17 relate to clinical worsening (material contribution to or aggravation of existing narcolepsy). The same medical events appear in both sets, but with slightly different temporal and evidentiary requirements. For example, concussion or moderate to severe traumatic brain injury within two years before onset (factor 1) and within two years before worsening (factor 9) are separately listed. This means a veteran who had narcolepsy before service and sustains a concussion during service may claim worsening if the concussion occurs within two years of a documented increase in symptom severity.

Time windows: Each factor has a specific period before clinical onset or worsening. For concussion and neurosurgical procedures, it is two years; for therapeutic brain radiation, three years; for neurological diseases involving the hypothalamus, midbrain or brainstem, two years; for Pandemrix vaccine and H1N1 infection, two years; for streptococcal pharyngitis, three years. The windows are based on the RMA’s assessment of the epidemiological evidence linking exposure to narcolepsy. They create strict temporal limits that may exclude claims where the interval is longer, even if the medical literature suggests a possible longer latency.

Interplay with other Statements of Principles: Section 11 incorporates by reference any other SoP that covers an injury or disease referred to in a factor. For example, “concussion or moderate to severe traumatic brain injury” is itself an injury that may have its own SoP. The factor requires the claimant to satisfy the definition and causation criteria of that other SoP as in force from time to time. This creates a cascading system of cross-references that can complicate claims.

The primary affected group is current and former members of the Australian Defence Force, veterans, peacekeepers and persons who rendered British nuclear test defence service, together with their dependents seeking compensation for narcolepsy or death from narcolepsy. Specifically, section 5 applies the instrument to claims under section 120A of the VEA or section 338 of the MRCA. This includes claims for disability pension, permanent impairment, special rate disability pension, and death benefits.

Secondary affected parties include the Repatriation Commission and the Military Rehabilitation and Compensation Commission as decision-makers, as well as the Veterans’ Review Board and the Administrative Appeals Tribunal on review. Medical practitioners who assess veterans for narcolepsy will need to ensure their diagnoses conform to the definition in section 7(2), including the exclusion of other causes and the use of appropriate clinical testing. Legal representatives and advocates must understand the factors and time windows to advise claimants.

The instrument also affects the Repatriation Medical Authority itself, which is required to keep the SoP under review and may amend or replace it as new medical evidence emerges. The repeal of the 2014 SoP means that anyone with a pending claim that had not been finally determined before 31 January 2022 will be assessed under the new instrument, unless transitional provisions in the VEA preserve the old standard.

From a compliance perspective, the instrument imposes administrative costs on claims processing. Decision-makers must verify whether the claimed factor is within the specified time window and meets the definitions (e.g., the clinical definition of narcolepsy, the exclusion of early onset, the requirement for diagnosis by MSLT or orexin measurement). This increases the evidentiary burden on claimants, who must produce medical records, sleep study results, and documentation of the triggering event (e.g., vaccination records, hospital admissions for TBI, swab results for streptococcal infection). The strict time windows may require claimants to establish medical events from years or decades ago, which can be difficult if records are incomplete.

In terms of economic incidence, the SoP concentrates costs on veterans with narcolepsy that does not fit the listed pathways. For example, a veteran whose narcolepsy began after an H1N1 infection but more than two years later would have no claim, even if medical evidence suggests a causal link. This is a deliberate trade-off: the RMA judged that the epidemiological evidence supports a two-year window, but individual outliers exist. The instrument thus creates legal certainty for the compensation system at the expense of potential under-compensation for some claimants.

The instrument does not impose duties on claimants directly; rather, it specifies the criteria that must be satisfied for a claim to succeed. The key “right” is the right to rely on any of the listed factors to raise a reasonable hypothesis. If a claimant has evidence of concussion within two years before onset, or of receiving the Pandemrix vaccine within two years before onset, they have a right to have that hypothesis considered by the decision-maker. The instrument does not guarantee the claim will succeed because the factor must also be related to relevant service, and the hypothesis must be reasonable on the whole of the evidence.

The Repatriation Medical Authority has a duty under the VEA to determine Statements of Principles based on sound medical-scientific evidence. Section 8 states that the RMA is of the view that such evidence exists for the factors it included. The Authority does not have a duty to include every possible factor; it exercises discretion within its statutory mandate. Claimants have no right to insist on factors not listed, though they can challenge the SoP itself only on limited judicial review grounds (such as error of law or jurisdictional error, not on the merits of the medical evidence).

The instrument imposes an evidential burden on claimants to prove the factor exists to the reasonable hypothesis standard. This is a lighter burden than the civil standard but still requires more than mere assertion. For clinical worsening, the claimant must also show that the narcolepsy existed before service and that the worsening factor is service-related (section 10(2)). The reference to “inability to obtain appropriate clinical management” (factor 17) is notable: it imposes no temporal window and does not require a specific medical event. Instead, it allows a claim where the veteran could not access proper treatment for narcolepsy, presumably because of service-related circumstances such as posting to a remote location or lack of specialist services. This factor could be used as a residual catch-all, but it still requires that the inability be related to relevant service.

Decision-makers have a duty to apply the instrument according to its terms. They cannot add or subtract factors, and they must interpret definitions strictly. The notes in section 7(2) provide guidance but are not binding. The instrument also incorporates other SoPs by reference (section 11), so decision-makers must have regard to those instruments as well, potentially creating a chain of dependencies. For example, to satisfy factor 1 (concussion or moderate to severe TBI), the decision-maker might need to consult the SoP for concussion to determine what constitutes “moderate to severe traumatic brain injury” and whether it must be service-related.

The Statement of Principles itself does not contain penalties. It is a legislative instrument that governs the causation standard for benefits. If a claim fails because no factor is established, the claimant is simply denied compensation. There are no fines or criminal sanctions for non-compliance with the SoP.

However, enforcement mechanisms exist under the VEA and MRCA for fraud. A claimant who knowingly provides false information to satisfy a factor could be prosecuted under the Criminal Code or have benefits recovered. The instrument indirectly creates incentives to avoid such conduct because the factors are reasonably specific: faking a concussion or a streptococcal infection would require fabrication of medical records.

From an economic perspective, the absence of penalties on the instrument does not mean it lacks coercive effect. The SoP effectively penalises claimants whose narcolepsy falls outside the listed pathways by denying them benefits. This is not a penalty in the legal sense but a distributional consequence. The instrument is enforcement-neutral in terms of administrative sanctions but enforcement-heavy in terms of claim outcomes.

The Repatriation Medical Authority has no enforcement role; its job ends with the making of the SoP. Enforcement of claim decisions is handled by the Commission and the tribunals. The SoP can be challenged on review, and if a decision-maker misapplies it, the claimant may seek merits review or judicial review. The instrument itself does not create a right of appeal; that comes from the parent Act.

The instrument is made under section 196B(2) of the Veterans’ Entitlements Act 1986. It operates within the framework of that Act, particularly section 120A which specifies the reasonable hypothesis standard. It also applies to claims under section 338 of the Military Rehabilitation and Compensation Act 2004 by virtue of section 5.

The most significant interaction is with other Statements of Principles. Section 11 provides that if a factor refers to an injury or disease for which another SoP exists (e.g., “moderate to severe traumatic brain injury”), then the factors in that other SoP apply as in force from time to time. This means a claimant who relies on factor 1 (concussion or moderate to severe TBI) must satisfy not only the temporal window and definitional criteria in this instrument but also the requirements of the SoP for TBI. If the TBI SoP requires a specific clinical test or excludes mild TBI, that exclusion flows through. This can create a chain that increases the compliance burden.

The instrument does not interact directly with the Safety, Rehabilitation and Compensation Act 1988 (the Comcare scheme) or the workers’ compensation laws of the states; it is specific to military compensation. However, veterans may also claim through Comcare for service-related conditions not covered by the VEA or MRCA, but the SoP would not apply there.

The definition of narcolepsy excludes conditions that cause daytime sleepiness from other sources, such as circadian rhythm disorders or insufficient sleep. This means the instrument interacts with clinical practice guidelines but not with other legislation directly. The exclusion of early onset narcolepsy likely reflects the RMA’s view that such cases are unlikely to be service-related, though the instrument does not give the rationale.

Note 4 lists examples of other conditions that can cause daytime sleepiness, including rotating shift work. This is directly relevant for veterans whose service involved shift work: if their sleepiness is attributable to shift work rather than narcolepsy, the claim fails regardless of the factors. This interaction with the VEA’s requirement that the disease itself be narcolepsy, not a symptom, is crucial.

This instrument is the second Statement of Principles concerning narcolepsy determined by the Repatriation Medical Authority. It repeals the previous SoP No. 7 of 2014 (Federal Register of Legislation identifier F2014L00023). That earlier instrument was also made under subsections 196B(2) and (8) of the VEA. The new instrument differs in several respects.

First, the 2014 SoP may have had different definitions or factors. The current instrument removes any reference to subsection 196B(8) (which concerns reasonable hypothesis for deaths and injuries that are not diseases) and relies only on subsection 196B(2) for diseases. This is consistent with narcolepsy being classified as a disease.

Second, the factors appear similar in structure but the wording and time windows may have changed. For example, the 2014 version included factors for H1N1 infection and Pandemrix vaccine; the current instrument retains them with the same two-year window. However, the current instrument adds factor 17 (inability to obtain appropriate clinical management) which did not appear in the 2014 version. This is a significant expansion of potential claims, as it is the only factor without a temporal limit.

Third, the current instrument explicitly excludes early onset narcolepsy, whereas the 2014 SoP may have included or excluded it differently. The notes on diagnosis and exclusions are more detailed in the new version, reflecting updated medical understanding.

The instrument was made on 24 December 2021 and commenced on 31 January 2022. It is a legislative instrument registered on the Federal Register of Legislation. There is no indication in the text that further amendments are pending; the RMA may update it again if new evidence emerges, but no schedule for review is provided.

Claimants and practitioners should note that the repeal of the 2014 SoP means that any claim finally determined before 31 January 2022 is not affected, but claims lodged after that date are subject to the new instrument. For claims that straddle the commencement date, transitional provisions in the VEA will determine which version applies. Typically, a claim is assessed under the SoP in force at the time of the decision, not at the time of the disease onset or the claim lodgement.

The instrument itself does not reference any litigation, and the source text contains no case citations. However, as a legislative instrument, it is subject to judicial review under the Administrative Decisions (Judicial Review) Act 1977, the High Court’s original jurisdiction under section 75(v) of the Constitution, and the appellate jurisdiction of the Federal Court. The reasonableness of the RMA’s determination of factors can be challenged on grounds such as jurisdictional error or failure to consider relevant material, but not merely because alternative factors were not included.

Notable avenues for challenge include whether the RMA correctly applied the standard of “sound medical-scientific evidence” required by section 196B(2). If a veteran or a representative can show that the RMA ignored significant medical evidence linking narcolepsy to another vaccine or infection, the SoP could be set aside. However, courts generally afford the RMA a wide margin of appreciation because the subject matter is technical.

The Administrative Appeals Tribunal often hears merits review of SoP-based decisions. In those proceedings, the instrument is binding unless the Tribunal finds that the factor does not support a reasonable hypothesis on the particular facts. The Tribunal does not have power to disregard the SoP itself; it can only decide whether the claim meets the factors.

There is no known litigation specifically concerning the 2014 narcolepsy SoP that would set a binding precedent for the 2022 version. Given the similarity of many factors, previous AAT decisions on concussion or Pandemrix claims under the old SoP may be persuasive but not binding.

Practitioners should be aware that the SoP is often a starting point for litigation. If a claim is rejected, the veteran can apply to the Veterans’ Review Board, then appeal to the AAT, and ultimately to the Federal Court on questions of law. The costs of such litigation are borne by the parties, which may discourage legitimate claims. The instrument thus contributes to the cost structure of veterans’ compensation administration.

Several provisions in the instrument are easily overlooked or can trip up claimants and practitioners.

Exclusion of early onset narcolepsy. Section 7(2)(c)(i) specifically excludes “early onset narcolepsy” without defining the term. The Dictionary does not define “early onset”. This creates interpretative uncertainty. Is it onset before age 18? Before age 10? The RMA may have intended to exclude cases that are congenital or develop before the person could have rendered relevant service, but without a definition, decision-makers may choose different thresholds. Claimants with onset in adolescence should seek contemporaneous medical records to confirm the exact age of onset, and if possible, get expert opinion that the onset was not “early”.

Strict exclusion of other causes of daytime sleepiness. Note 4 lists examples of conditions that can cause daytime sleepiness and are not narcolepsy. Critically, “rotating shift work” is listed. If a veteran’s sleepiness is primarily due to a history of shift work rather than narcolepsy, the claim fails even if they also have some narcoleptic features. This places a heavy evidentiary burden on the claimant to prove that the condition is narcolepsy and not merely a consequence of service-related rosters.

Pandemrix only, not other H1N1 vaccines. Factor 6 and 14 specify “the adjuvanted influenza H1N1 vaccine PandemrixTM”. Other H1N1 vaccines, including those with a different adjuvant or manufactured by other companies, are not listed. This is despite medical literature suggesting a link between narcolepsy and other pandemic influenza vaccines (e.g., Arepanrix in Canada). Claimants who received a different vaccine cannot use this factor. The RMA presumably judged that the evidence only supports Pandemrix, but the exclusion may be under-inclusive.

Streptococcus pyogenes pharynx infection only. Factor 8 and 16 require infection of the pharynx with Streptococcus pyogenes specifically. Other group A streptococcal infections (e.g., skin infections) or other bacterial pharyngitis do not qualify. The three-year window for this factor is longer than the two-year windows for most others, but it still requires proof of the specific organism, which may not be available if the infection was diagnosed clinically without a swab.

Clinical worsening requires pre-existing narcolepsy before service. Section 10(2) states that factors 9 to 17 apply only where narcolepsy was suffered or contracted before or during (but did not arise out of) relevant service. If the narcolepsy arose out of service, then the onset factors (1-8) would apply, not worsening. This means a veteran who develops narcolepsy for the first time during service must use the onset factors; they cannot fall back on worsening if the onset factor window has passed. Practitioners must take care to characterise the temporal sequence correctly.

Neurosurgical procedure “involving the hypothalamus, midbrain or brainstem”. Factors 2 and 10 require a procedure involving these specific regions. A general neurosurgical procedure on the head may not qualify if it did not affect those areas. Medical evidence must link the procedure to those anatomical structures.

Factor 17 (inability to obtain appropriate clinical management) has no time limit. This factor is a double-edged sword. It could rescue a claim where the veteran’s narcolepsy worsened because they could not access treatment due to service circumstances (e.g., deployment to a remote area). However, it is vague and likely to be contested. Decision-makers may require evidence that the inability was not merely a choice but a genuine barrier related to service. The absence of a time window means it can apply to any aggravation regardless of when it occurred, but the worsening must still be “material”.

Cross-references to other SoPs. Section 11 means that interpreting each factor often requires reading another legislative instrument. For example, to know what “moderate to severe traumatic brain injury” means, one must find the current SoP for TBI. That SoP may itself contain exclusions or time windows. The chain can create unexpected disqualifications. Practitioners must compile the entire set of relevant SoPs.

Compliance with this Statement of Principles is not about avoiding penalties but about successfully navigating the compensation claim process. The instrument is a tool for decision-makers and claimants; compliance means ensuring that the claim meets the technical requirements.

For claimants and their representatives:

1. Confirm the diagnosis. Obtain a definitive diagnosis of narcolepsy that meets the definition in section 7(2). This means clinical sleepiness for at least three months, with or without cataplexy, confirmed by multiple sleep latency test or orexin measurement. The diagnosis must exclude early onset and other causes of daytime sleepiness. A specialist sleep physician’s report is essential.

2. Identify the applicable factor. Review the 17 factors and determine which one(s) could apply. Obtain contemporaneous medical records (e.g., hospital notes for concussion, vaccination records for Pandemrix, throat swab results for Streptococcus pyogenes). For traumatic brain injury, obtain neuroimaging or neurological reports establishing moderate to severe severity. For factor 17, document any service-related barriers to accessing treatment, such as lack of specialist availability at a remote posting.

3. Establish the time window. For each factor, calculate the date of clinical onset or clinical worsening. Onset is the first appearance of the core symptoms meeting the definition. Worsening is a material increase in symptom severity above the pre-existing baseline. Ensure the triggering event occurred within the specified window (two years for most factors, three years for radiation and strep infection). If the window has passed, consider whether factor 17 (no time limit) might apply if the inability to obtain clinical management caused the worsening.

4. Link the factor to relevant service. The factor must be related to the person’s operational, peacekeeping, or other listed service. For example, if the factor is concussion, the concussion must have occurred during service (or be attributable to service). For Pandemrix, the vaccine must have been administered as part of a service requirement. For inability to obtain clinical management, the inability must be due to service circumstances.

5. Consider worsening versus onset. If the narcolepsy existed before service, only factors 9 to 17 can be used, and only if the condition did not arise out of service. Provide evidence of the pre-service diagnosis and the service-related event that caused worsening.

6. Check cross-referenced SoPs. If the factor refers to an injury like concussion or brain neoplasm, find the current SoP for that injury and ensure the definition and factors are satisfied. The SoP for TBI may require a Glasgow Coma Scale score or other criteria.

For decision-makers:

1. Interpret definitions strictly. The terms in the Dictionary and the notes have specific meanings. For example, “cataplexy” must be transient generalised weakness triggered by emotion, not just muscle fatigue. “Sleep paralysis” is defined narrowly as inability to move for one to two minutes upon awakening. Ensure medical reports use these definitions.

2. Check for exclusions. Verify that the diagnosis is not early onset and that other causes of daytime sleepiness are excluded. Request clarification from the medical assessor if the report mentions rotating shift work or medication side effects.

3. Verify the time window. The claimant must prove not only that the event occurred but that it occurred within the specified period before onset or worsening. If the onset date is unclear, the decision-maker should seek expert opinion on the probable date of first symptoms.

4. Apply the correct standard of proof. The instrument uses “reasonable hypothesis”, which requires that the factor as a minimum exist. The decision-maker must ask: on the whole of the medical evidence, does the factor support a hypothesis that is reasonable, not fanciful? This is a low threshold, but if the evidence is contradictory, the decision-maker may still find the hypothesis not reasonable.

5. Document reasons. The decision record should identify which factor is considered, why it is or is not met, and how the relationship to service is established. This facilitates review. If factor 17 is raised, explain why the inability to obtain clinical management is or is not related to service.

Compliance with this SoP is ultimately about precision. The instrument is designed to create clear causal pathways. Claimants who cannot fit their facts into one of the pathways will likely fail, regardless of the medical plausibility of an alternative causal chain. The instrument does not require the RMA to update factors based on new evidence, so periodic review of the SoP’s currency is advisable for practitioners handling multiple claims.